melanoma
BriaCell advances personalised skin cancer immunotherapy vaccine candidate
Around 112,000 new cases of skin cancer will be diagnosed in the US in 2026
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
Cases of skin cancer set to reach 263,000 in 2035 according to new report
The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe
NHS programme to give melanoma patients fast-track access to skin cancer vaccine
The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma
British Skin Foundation receives £10,000 donation from Circle Health Group
The healthcare provider’s previous donation is supporting research into early melanoma detection
Merck shares positive ten-year results for Keytruda in advanced melanoma
More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year
BioNTech shares promising results for mRNA immunotherapy candidate in advanced melanoma
Melanoma is currently responsible for around 58,000 deaths globally every year
Moderna/Merck share positive three-year results for investigational skin cancer vaccine
More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024
FDA approves Iovance’s Amtagvi as first cellular therapy for advanced melanoma
Amtagvi is now the first one-time, individualised T cell therapy to be approved in the US for a solid tumour cancer
Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma
Approximately 17,000 cases of melanoma are diagnosed in the UK every year
Bristol Myers Squibb’s Opdivo approved by FDA for expanded melanoma use
More than 97,000 cases of melanoma are expected to be diagnosed in the US in 2023
Bristol Myers Squibb to acquire Mirati Therapeutics for up to $5.8bn
The transaction would mark a significant boost to the US drugmaker’s oncology portfolio